Achillion Pharmaceuticals (ACHN) Shares are Down -6.79%

On a relative basis, the stock has outperformed the S&P 500 by 0.29% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The 4-week change in the price of the stock is -0.25% and the stock has fallen -6.79% in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.61% and the 50-Day Moving Average is 4.31%.The 200 Day SMA reached 2%


Achillion Pharmaceuticals (NASDAQ:ACHN): After opening at $7.98, the stock dipped to an intraday low of $7.89 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.145 and the buying power remained strong till the end. The stock closed at $8.1 for the day, a gain of 2.14% for the day session. The total traded volume was 1,095,631. The stocks close on the previous trading day was $8.1.

Achillion Pharmaceuticals (ACHN) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $17 and the lowest price target forecast is $5. The average forecast of all the analysts is $10.5 and the expected standard deviation is $4.41.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.